secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001193125-25-328759
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma CLO George Lloyd to step down; Arthur McGivern to assume role Jan 1, 2026
--------------------------------------------------------------------------------

- George W. Lloyd transitions from EVP and Chief Legal Officer effective Dec 31, 2025.
- Lloyd will remain employed as a senior advisor to the Company.
- Arthur R. McGivern, EVP and General Counsel, assumes CLO responsibilities on Jan 1, 2026.
- McGivern joined Royalty Pharma in Oct 2022 from Goodwin Procter LLP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525328759/0001193125-25-328759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525328759/d938129d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-328759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer